<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types
Background Image

Find the Right Syngeneic Model

Accelerate immunotherapy research with reliable, preclinical data

Find the perfect syngeneic model to accelerate your immunotherapy discoveries. Explore a reliable source for preclinical data.

Preclinical research of new immunotherapies requires in vivo models with fully functional immunity. Syngeneic tumor models are homografts derived from immortalized mouse cancer cell lines which originated from the same inbred strain of mice. This provides simple models with fully competent immunity for assessing your new single agent and combination immunotherapies.

Well Validated Models

Chart demonstrating well-validated models.Evaluation of Anti-PD-1 Efficacy

Our syngeneic models are well-characterized, making them the ideal models to evaluate your novel immuno-oncology agents as well as combination therapies.

The extensive characterization data found within our searchable database MuBase® includes immune checkpoint inhibitor benchmarking (including model response to anti-PD-1, PD-L1, and CTLA-4) and tumor RNAseq. Baseline tumor immunoprofiling and post-ICI treatment tumor immunoprofiling is also available for a subset of our models with further characterization ongoing.

Learn More

Explore our collection:

We provide a large collection of syngeneic models covering a variety of cancer types and immune phenotypes, available now for your efficacy and PD studies.

Subcutaneous Models

Bladder Cancer - Syngeneic Models Bladder: MBT-2
Glioma Cancer - Syngeneic Models Glioma: GL261-luc
Leukemia - Syngeneic Models Leukemia: C1498
Neuroblastoma: N1E-115, Neuro-2a
Plasmacytoma: J558
Breast Cancer - Syngeneic Models Breast: 4T1, EMT6, JC
Fibrosarcoma - Syngeneic Models Fibrosarcoma: WEHI-164
Kidney Cancer - Syngeneic Models Kidney: Renca
Liver: H22, Hepa 1-6
Myeloma: MPC-11, P3X63Ag8U.1
Pancreatic: Pan02
Prostate: RM-1

Orthotopic Models

Breast: 4T1, EMT6
Liver: Hepa 1-6
Glioma: GL261-luc
Pancreatic: Pan02

Systemic Models

Leukemia: C1498
Myeloma: MPC-11

Specialty Models

Breast: 4T1 (metastatic/bioluminescent)
Glioma: GL261-luc (bioluminescent)
Melanoma: B16-F-10 (metastatic), B16-BL6 (metastatic)
Liver: H22 (bioluminescent) Hepa 1-6 (bioluminescent)
Lung: LL/2 (LLC1) (metastatic)
View Our Full Collection

Advanced Models for Metastatic Modeling and Optical Imaging 


We provide syngeneic models of metastasis as well as orthotopic and bioluminescent models. This allows you to study clinically relevant metastatic invasion, metastatic lesions in secondary organs, and to evaluate your agents which target metastasis.

Our orthotopic models provide a tumor microenvironment more comparable to the patient. The tumors form at organ-specific sites, facilitating metastatic spread, and supporting immune and stromal component interactions.

Our bioluminescent imaging (BLI) capabilities enable non-invasive longitudinal monitoring of orthotopic tumor burden. This provides you with optimal randomization, reduction of false positives, and continuous feedback, supporting the most appropriate treatment regimens mid-study.

Discover Our Advanced Models


Discover Large Scale In Vivo Screening for Immunotherapeutics 


Fast-track the screening of your novel immunotherapeutics with MuScreen™, our large-scale, in vivo screening platform for cancer immunotherapeutics.

MuScreen can improve efficiency and save you study time by helping you to rapidly identify the right markers and models for your preclinical programs. Evaluate your agent's TGI and PD effects with either the Syngeneic Efficacy or PD Screening Panel of 6 or 12 models.

Learn More

Discuss Your Syngeneic Tumor Models Project

Tell us how we can help